EMulate Therapeutics Announces Poster Presentation of Its Confirmatory Pre-Clinical Pain Study Results at the 15th Annual Pain Therapeutic Summit at Washington, D.C. (Nov 1-3)
SEATTLE, WA / ACCESSWIRE / October 29, 2021 / EMulate Therapeutics, Inc. (EMulate) announced today its involvement in, and presentation of its pre-clinical pain results at, the 15th Annual Pain Therapeutic Summit.
ANS’s analysis using its ALGOGram™ screen, as well as EMulate’s own analysis, discovered that EMulate’s fentanyl, hydromorphone, CBD, dexamethasone, naproxen and indomethacin signals showed pain inhibition effects. The recent confirmatory studies done at the ANS labs were powered to detect statistically significant activity in these pain models.
The ANS Biotech confirmatory assays tested five different pain models (acute, tonic, neuropathic, inflammatory and visceral). In the assays, three selected signals showed excellent pain‑reducing effects: naproxen, fentanyl & CBD. In the case of two of those signals, the effects measured were equivalent to or better than the effects of the physical reference drugs. No adverse events or toxicities were noted or observed in these assays.
“These results continue to validate that our technology emulates the effects of many drugs and chemicals,” stated Dr. Xavier Figueroa, EMulate’s Vice President of Pre-Clinical Development. “These data support other assays we have conducted in multiple biological models, including human clinical trials, indicating that Radio Frequency Energy (RFE) focused at the ultra-low end of the energy spectrum (ulRFE®) may be able to provide beneficial clinical effects without the use of chemicals or drugs, which in this case could be a game changer for many people suffering from acute or chronic pain and other physical maladies. It is exciting to share with the research and business communities the results of our pre-clinical studies. We look forward to engaging with researchers and business development groups on how best to partner and bring to the forefront EMulate Therapeutic’s technology,” Dr. Figueroa said. Dr. Figueroa will be presenting these data at the Summit.
The 15th Annual Pain Summit will be held virtually and live-streamed November 1st thru 3rd, with leading researchers and business leaders sharing the latest developments and opportunities in the field of pain research and pain management.
About EMulate Therapeutics
EMulate Therapeutics is a clinical-stage company utilizing its proprietary ulRFE technology to provide safe and effective therapeutic benefits. The company has generated encouraging data in patients afflicted with glioblastoma and diffuse midline glioma. It has also generated encouraging preclinical data in pain and mental health models, as well as in animal health and bio-agriculture. EMulate Therapeutics is also the licensor of its proprietary technology to its subsidiary, Hapbee Technologies, Inc. (HAPB:TSVX). Hapbee is a commercial-stage consumer technology company.
Company Contact:
David Matteson
dmatteson@emultatetx.com
Cell: 425/478-2121
Investor Contact
James Carbonara
Hayden IR
Tel (646) 755-7412
james@haydenir.com
SOURCE: EMulate Therapeutics Inc
View source version on accesswire.com:
https://www.accesswire.com/670413/EMulate-Therapeutics-Announces-Poster-Presentation-of-Its-Confirmatory-Pre-Clinical-Pain-Study-Results-at-the-15th-Annual-Pain-Therapeutic-Summit-at-Washington-DC-Nov-1-3
